Systemic Sclerosis Patients Treated With Oral Treprostinil Diethanolamine PDF Print E-mail
Wednesday, 12 June 2013 20:55
Patients with systemic sclerosis effectively absorbed oral treprostinil diethanolamine, which produced a temporal association with improved cutaneous perfusion and temperature, according to study results. In a dual-center, open-label, phase 1 study, researchers evaluated 19 patients with systemic sclerosis (SSc; mean age, 48 years; 84.2% women; 89.5% Caucasian; 53% limited SSc). Eleven patients had an active digital ulcer at baseline. Treprostinil diethanolamine sustained release (SR) was administered to patients with dose titration up to 4 mg twice daily.

Laser Doppler imaging quantified drug concentrations and perfusion, which were measured across 12 hours at 2 mg or 4 mg (or maximally tolerated) doses. Individual plasma concentration vs. time profiles using noncompartmental analysis methods determined pharmacokinetic parameters.

“Digital perfusion and skin temperature were modeled as a function of log-transformed drug concentration and other covariates by performing repeated measures analyses using random effects models,” the researchers wrote.

Sixteen patients completed the 8-week study. Approximately 3.6 hours after administration of treprostinil diethanolamine, peak plasma concentrations reached means of 1,176 pg/mL and 2,107 pg/mL for 2-mg and 4-mg doses, respectively. Overall exposure (AUC from 0 to 12 hours) was linear between doses and observed at 7,187 hr*pg/mL for 2-mg and 12,992 hr*pg/mL for 4-mg doses. Log-transformed plasma at the 4-mg dose had a positive association with perfusion (P=.015) and digital skin temperature (P=.013).

The most common adverse events were headache (89%), diarrhea (47%) and nausea (42%), which were similar to those seen with prostacyclin analogs. No serious adverse events or deaths were reported.

“Currently prostacyclin analogs are administered via intravenous or subcutaneous routes in [systemic sclerosis] patients with vascular complications,” the researchers concluded. “Our data show that oral SR formulation of treprostinil diethanolamine was effectively absorbed in patients with SSc, was associated with improved cutaneous perfusion and temperature with short-term treatment, and may provide a new therapeutic option for Raynaud’s phenomenon and peripheral vascular disease of SSc.”

Source: Helio
 
More articles :

» Scientists Identify Agent That Can Block Fibrosis of the Skin and Lungs

Researchers at the have identified an agent that in lab tests protected the skin and lungs from fibrosis, a process that can ultimately end in organ failure and even death because the damaged tissue becomes scarred and can no longer function...

» Musculoskeletal Rehabilitation in the Person with Scleroderma

Janet L. PoolePosted: 03/12/2010; Curr Opin Rheumatol. 2010;22(2):205 © 2010 Lippincott Williams & WilkinsAbstractPurpose of Review: The purpose of this review is to examine current evidence for the efficacy of rehabilitation techniques for...

» Calcium Deposits Under the Skin

Numerous health effects or conditions are associated with calcinosis or calcium deposits under the skin. According to the , calcinosis is the medical term for calcium deposits that can form under the skin or in the muscles. Calcium deposits in these...

» Study Reveals New Genetic Link To Scleroderma

An international research consortium including scientists from T (UTHealth) has identified a new genetic link to the systemic form of . Researchers believe a thorough understanding of the genetic nature of the disease is crucial to developing a...

» Face Exercises for Scleroderma

Scleroderma is caused by too much collagen in your body, which causes hardening, thickening and tightening of your skin and connective tissues. In localized scleroderma, only your skin is involved; systemic scleroderma damages your inner organs,...

» A System Out of Breath: How Hypoxia Possibly Contributes to the Pathogenesis of Systemic Sclerosis

T. W. van Hal, L. van Bon, and T. R. D. J. RadstakeReceived 20 May 2011; Revised 18 August 2011; Accepted 7 September 2011Systemic sclerosis (SSc) is typified by vascular alterations and immunological disturbances and fibrosis of the skin and...